otelixizumab
Otelixizumab, also known as TRX4, is a monoclonal antibody, which is being developed for the treatment of type 1 diabetes and other autoimmune diseases. The antibody is being developed by Tolerx, Inc. in collaboration with GlaxoSmithKline and is being manufactured by Abbott Laboratories. — Wikipedia
Clinical trial activity
9 trials · 7 clinical orgs · 0 marketing orgs
Earliest trial started Jun 1, 2000 (NCT00627146)
Timeline
Indications
Mechanism of action
- T-cell surface glycoprotein CD3 epsilon chainBINDING AGENT
CD3E binding agent
Modulates the T-cell receptor (TCR)¿CD3 complex resulting in the cells becoming 'blind' to antigen (a process that is also known as antigenic modulation). In addition, the monoclonal antibody preferentially induces anergy or apoptosis of activated T cells through alterations in TCR-mediated signal transduction.
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOtelixizumab ↗
- ChEMBLCHEMBL2109251 ↗
- ChEMBLCHEMBL1743053 ↗
Also known as
- chaglycd
- chaglycd3
- chagly cd3
- chagly cd3
- otelixizumab
- otelixizumab
- otelixizumab
- trx-4
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02000817 | Phase 2 | Mar 12, 2014 | GlaxoSmithKline, Parexel |
| NCT01222078 | Phase 2 | Nov 1, 2010 | GlaxoSmithKline |
| NCT01114503 | Phase 2 | Jul 1, 2010 | GlaxoSmithKline |
| NCT01123083 | Phase 3 | May 1, 2010 | GlaxoSmithKline, Juvenile Diabetes Research Foundation |
| NCT01077531 | Phase 1 | Apr 28, 2010 | GlaxoSmithKline |
| NCT00946257 | Phase 1 | Jul 8, 2009 | GlaxoSmithKline |
| NCT00678886 | Phase 3 | Jul 1, 2008 | GlaxoSmithKline, Juvenile Diabetes Research Foundation |
| NCT00451321 | Phase 2 | Jul 1, 2006 | GlaxoSmithKline, Juvenile Diabetes Research Foundation |
| NCT00627146 | Phase 2 | Jun 1, 2000 | Erasmus University Rotterdam, Free University of Brussels, Katholieke Universiteit Leuven, University of Antwerp |
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 8 | 8 | 3 | 2006 |
| Juvenile Diabetes Research Foundation | Academic/Hospital | 3 | 0 | 2 | 2006 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 0 | 1 | 2000 |
| Free University of Brussels | Academic/Hospital | 1 | 1 | 1 | 2000 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 0 | 1 | 2000 |
| Parexel | For profit | 1 | 0 | 1 | 2014 |
| University of Antwerp | Academic/Hospital | 1 | 0 | 1 | 2000 |